Chimeric Therapeutics Ltd. (AU:CHM) has released an update.
Chimeric Therapeutics Limited has announced an Extraordinary General Meeting (EGM) scheduled for June 11, 2024, aiming to refresh the company’s share issuance capacity. The EGM will address the ratification of past shares and options issues, and seek approval for a potential issuance of up to 800 million shares to support clinical trials and general working capital. The Executive Chairman urges shareholders to endorse the proposed resolutions to enable swift financial maneuvering without the delay of additional meetings.
For further insights into AU:CHM stock, check out TipRanks’ Stock Analysis page.
